Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lercanidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | RAB9A | P51151 | 2/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | MLNR | O43193 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | CNR1 | P21554 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lercanidipine SCHEMBL2964657 | 1.00 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8630225 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL217099 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL29349606 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9901189 | 0.98 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9901187 | 0.98 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25268 | 0.98 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8415026 | 0.98 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9957683 | 0.98 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25269 | 0.98 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772401-B2 | Process for the preparation of lercanidipine | HETERO DRUGS LIMITED (IN) | 2010-08-10 | — | — | US | disclosed |
| US-20100087653-A1 | NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | HETERO DRUGS LIMITED (IN) | 2010-04-08 | — | — | US | disclosed |
| US-7687653-B2 | Process for the preparation of lercanidipine | HETERO DRUGS LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| EP-1891009-B1 | A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | HETERO DRUGS LTD (IN) | 2009-10-14 | — | — | EP | disclosed |
| US-20090227800-A1 | NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | HETERO DRUGS LIMITED (IN) | 2009-09-10 | — | — | US | disclosed |
| WO-2008040367-A1 | LERCANIDIPINE HYDROBROMIDE, A PROCESS FOR ITS PREPARATION, CRYSTALLINE FORMS AND COMPOSITIONS THEREOF | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2008-04-10 | — | — | WO | disclosed |
| EP-1891009-A1 | A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | Hetero Drugs Limited (IN) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006134606-A1 | A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | HETERO DRUGS LIMITED (IN) | 2006-12-21 | — | — | WO | disclosed |
| EP-0824517-B1 | A PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI CHEM PHARM (IT) | 2002-07-24 | — | — | EP | disclosed |
| US-5912351-A | 2,N-DIMETHYL-N-(3,3-DIPHENYLPROPYL)-1-AMINO-2-PROPANAL IN AN APROTIC SOLVENT REACTED WITH 2,6-DIMETHYL-5-METHOXYCARBONYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3 -CARBOXYLIC ACID; RECRYSTALLIZING LERCANIDIPINE CHLORIDE IN A SOLVENT MIXTURE | RECORDATI, S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-06-15 | — | — | US | disclosed |
| US-5767136-A | ADMINISTERING TO REDUCE MIGRATION OF CELLS, REDUCE BUILD UP OF CONNECTIVE TISSUE, OR PREVENT LIPID ACCUMULATION IN THE BLOOD VESSELS | RECORDATI, S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-06-16 | — | — | US | disclosed |
| EP-0824517-A1 | A PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035668-A1 | A PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087653-A1 | NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | TRPC1, DRD4, HTR1D | CACNA1C 16/4885ADORA3 3114/4885ADRA1A 55/4885 |
| US-20090227800-A1 | NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE | DRD4, PNMT, HTR4 | CACNA1C 36/4885ADORA3 2588/4885ADRA1A 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.